Beth Hoffman, Ph.D. is Founder, President and CEO at Origami Therapeutics. She brings more than 25 years of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain and psychiatry. Prior to Origami, she was Vice President, Discovery Biology for Vertex Pharmaceuticals, where she generated and launched clinical candidates for respiratory and neurological diseases, including first-in-class blockbuster drugs in cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta). She expanded the market for Orkambi and increased sales to over $1 billion, and also generated a novel non-opioid pain therapeutic and other protein folding programs at Vertex. Dr. Hoffman received an A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from Johns Hopkins University. She is a member of the Board of Trustees for the Huntington’s Disease Society of America as well as a Scientific Advisor for the Tau Consortium focusing on alleviating diseases associated with tau pathology, such as Alzheimer’s Disease. She is also on the Board of Biofrontera Inc. (NASDAQ:BFRI).